Censa Pharmaceuticals Inc is a global biopharmaceutical company based in Wellesley Hills, MA. With a focus on rare diseases, they have been delivering transformative therapies for over 25 years. Through their scientific platforms, they develop innovative treatments that address the underlying causes of diseases, providing more moments for patients.
PTC's research platforms include splicing modulation to control protein production and targeting oxidative stress and inflammation pathways to treat CNS diseases. They have achieved significant milestones, such as the first approved treatment for Duchenne muscular dystrophy and the first approved gene therapy directly infused into the brain. With a commitment to patients and a passion for science, PTC continues to expand their pipeline and develop treatments using the latest technologies available.
Generated from the website